Fas antigen (Fas) is a cell surface receptor molecule that mediates apoptosis-inducing signals into activated and/or autoreactive peripheral T and B cells by stimulation with Fas ligand or agonistic anti-Fas mAb. The i.p. administration of the hamster anti-mouse Fas mAb RK-8, which induced apoptosis both in vivo and in vitro, did not kill adult mice, whereas those given another hamster anti-mouse Fas mAb Jo2 rapidly die of fulminant hepatitis with hemorrhage. Here, we report that MRL-gld/gld mice thoroughly recovered and/or were prevented from glomerulonephritis, arthritis, sialadenitis, vasculitis and lymphoadenopathy after receiving a single administration of the agonistic anti-mouse Fas mAb RK-8. The serum levels of autoantibodies were decreased after the administration. All the therapeutic effects of RK-8 persisted for Ͼ6 months. These findings suggest that the systemic administration of agonistic anti-Fas mAb without fulminant hepatitis-inducing activity is a useful therapeutic strategy for treating systemic autoimmune disease.
Introduction
Fas antigen (Fas; APO-1/CD95) is a cell surface protein belonging to the tumor necrosis factor (TNF)/nerve growth factor receptor family and it mediates apoptosis-inducing signals upon stimulation with agonistic anti-Fas mAb (1) (2) (3) or Fas ligand (FasL) (4, 5) . FasL is a member of the TNF family and it is expressed on activated T cells (5) . In the immune system, Fas and FasL induce apoptosis in activated peripheral T and B cells, and thymocytes (6) (7) (8) (9) (10) (11) (12) (13) . The Fas-FasL system has been implicated in the regulation of homeostasis of peripheral T and B cells, and in T cell-mediated cytotoxicity.
Loss-of-function mutations of mouse Fas and FasL have been identified as the spontaneous mouse mutations, lpr (lymphoproliferation) and gld (generalized lymphoproliferative disease) respectively (14, 15) . Both types of mutant mice develop lymphadenopathy due to the influx of abnormal T cells expressing CD3, Thy-1 and B220 but not CD4 and CD8 accessory molecules. Moreover, in the serum of these mice, the levels of anti-DNA antibodies increase with age (16, 17) . When these mutants are introduced into an MRL background, mice spontaneously develop a more severe lupus-like systemic autoimmune disease with associated glomeruloCorrespondence to: S. Yonehara Transmitting editor: S. Nagata Received 9 May 1997, accepted 18 August 1997 nephritis, vasculitis, sialadenitis and arthritis (16) (17) (18) (19) (20) . The lpr or gld mutation is responsible for the early onset of systemic autoimmune disease in MRL mice. In humans, mutations of the gene encoding Fas and/or undetectable cell surface expression of Fas have been identified in patients with severe autoimmune disorders (21, 22) . Immunoregulatory defects resulting from the inability of lymphocytes to respond to Fas-FasL-mediated apoptosis lead to the early onset of autoimmune syndrome, suggesting that autoreactive immunocytes are eliminated by the function of the Fas-FasL system. We prepared the anti-mouse Fas mAb RK-8, which induced apoptosis in vitro against target cells expressing an allotype of Fas of BALB/c and MRL mice (23) . The in vivo administration of RK-8 is not lethal in adult BALB/c and MRL mice (24) , although the anti-mouse Fas mAb Jo2 is lethal in normal mice (24, 25) . Histological analyses of mice injected with RK-8 indicated severe damage of the thymus, and moderate damage of the spleen and liver. These in vivo effects of anti-Fas RK-8 were transient, because the thymus, liver and spleen recovered completely within 1 month after administration.
Since Fas plays an important role in the elimination of activated and/or autoreactive peripheral T and B cells, we wondered what would be the impact of antibody-mediated elimination of Fas-bearing cells on the course of a systemic autoimmune disease.
Methods

Antibodies and mice
Preparation and purification of hamster anti-mouse Fas mAb RK-8 and rat anti-mouse Fas mAb were performed as described previously (23, 24) . The MRL strain of mice bearing the gld mutation was established as described previously (20 
Histological analysis
The lymph nodes, kidneys, salivary glands and lungs were fixed in 10% formalin in 1 mM phosphate buffer, pH 7.2, embedded in paraffin, and then stained with hematoxylin & eosin. The hind paw including the ankle joint and other organs were fixed with 15% formalin in cold PBS. The joint tissue was decalcified in EDTA/formalin solution and then the tissue was embedded in paraffin. The incidence of glomerulonephritis and arthritis was calculated as follows. An individual positive (ϩϩϩ, ϩϩ and ϩ) for glomerulonephritis was defined as one having at least mesangial and/or endocapillary proliferative glomerular lesions with infiltration of mononuclear cells in Ͼ50, 10 and 5% of 20 renal glomeruli respectively. For a diagnosis of arthritis, an individual exhibiting synovial proliferation and/or pannus formation in at least one knee or foot joint was defined as positive.
Serum levels of anti-DNA antibodies
Relative amounts of anti-single-stranded DNA and anti-doublestranded DNA Ig (IgG ϩ IgM) were determined by ELISA using horseradish peroxidase-conjugated rabbit anti-mouse IgG ϩ IgM (Sigma, St Louis, MO) according to a method previously described (26) .
Results
In vivo administration of anti-mouse Fas mAb RK-8 into MRLgld/gld mice
To analyze the in vivo effects of anti-Fas mAb RK-8 against systemic autoimmune disease and lymphoadenopathy, purified RK-8 (5 mg/kg mouse) was i.p. injected once into MRLgld/gld mice at stages I (5 weeks old with no sign of disease), II (13-15 weeks old and developing autoimmune disease and lymphadenopathy) and III (21 weeks old with severe autoimmune disease including glomerulonephritis, arthritis, sialadenitis and vasculitis). In vivo effects of RK-8 were analyzed 1 and 2 months after administration into mice of stage III, and stages I and II respectively. The results are summarized in Table 1 .
Amelioration of lymphoadenopathy and splenomegaly
Lymphadenopathy and splenomegaly were completely ameliorated in stage II and III mice given RK-8 ( Fig. 1A and Table 1 ). Cells in the lymph node, spleen and thymus of stage III mice 1 month after receiving RK-8 were analyzed by cytofluorometry. The results indicated that the number of abnormal T cells (gld cells) expressing both Thy-1 and B220 dramatically decreased in all of these organs (Fig. 1C) . We detected Fas expression on gld cells by cytofluorometry (data not shown) and histological analyses showed many apoptotic bodies in lymph nodes 2 days after injecting RK-8 ( Fig. 1B) . RK-8 may directly induce apoptosis on gld cells in vivo, because it is unlikely to induce antibody-dependent cellular toxicity and complement-mediated cytotoxicity as reported (24) . In stage I gld mice treated with RK-8, lymphoadenopathy and splenomegary were not observed for Ͼ6 months (data not shown), suggesting that RK-8 directly killed not only gld cells expressing Fas but also progenitors of gld cells in vivo. Thus, RK-8 can thoroughly ameliorate and prevent lymphoadenopathy and splenomegaly in gld mice.
Amelioration of glomerulonephritis MRL-gld/gld mice Ͼ3 months develop systemic autoimmune disease (20) . In the kidney, glomerulonephritis was characterized by endocapillary proliferative lesions with associated infiltration of mononuclear cells, proliferation of mesangial cells and crescent formation (Fig. 2C) . These glomerular lesions revealed deposits of Ig and C3 (the third component of complement) in immunohistochemistry (data not shown). The glomerulonephritis was significantly ameliorated by RK-8 in all stages ( Fig. 2D and Table 1 ). Moreover, vascular lesions in the kidney which manifested granulomatous arthritis associated with the accumulation of mainly CD4 ϩ T cells and macrophages (17) (18) (19) (20) (Fig. 2A) were ameliorated in stage II and III mice given RK-8 (Fig. 2B) . Amelioration of both lesions might be induced by RK-8-mediated apoptosis in the infiltrating inflammatory cells involving T cells and macrophages. In stage I gld mice given RK-8, glomerulonephritis was prevented for Ͼ6 months (data not shown), suggesting that RK-8 directly killed silent autoreactive immunocytes in young stage I gld mice.
Effects of RK-8 on the salivary gland and the lung of MRL-gld/ gld mice In the salivary gland of MRL-gld/gld mice, inflammatory lesions were observed with associated infiltration of mononuclear cells around excretory ducts (Fig. 2E) . The inflammation of MRL-gld/ gld mice in salivary glands may be regarded as a model of Sjö gren's syndrome in humans as well as MRL-lpr/lpr mice (16, 17) . The infiltrating lymphoid cells in the salivary gland were completely eliminated and inflammation in the salivary glands of MRL-gld/gld mice was ameliorated by RK-8 (Fig. 2F) . The infiltrating lymphocytes may be directly eliminated through apoptosis caused by RK-8, since the infiltrating cells were chronically activated peripheral T cells that are sensitive to Fas- a -, normal; ϩ, positive. Effects on lymphadenopathy and splenomegaly shown in Fig. 1 are summarized. b -, normal; ϩ, 5-10% glomeruli positive; ϩϩ, 10-50% positive; ϩϩϩ, Ͼ50% positive. The incidence of glomerulonephritis was calculated as described in Methods.
c -, normal; ϩ, positive. The incidence of arthritis was determined as described in Methods. d ϩ, weakly positive; ϩϩ, positive. Effects on serum level of anti-single-stranded DNA and anti-double-stranded DNA shown in Table 2 are summarized. mediated apoptosis (9, 10, 23, 27, 28) . In the lung of MRL-gld/ gld mice, RK-8 caused essentially the same effects (elimination of infiltrated mononuclear cells around the artery and in alveolar septa, and amelioration of inflammation; data not shown).
Amelioration of arthritis
As shown in Fig. 2(G) , MRL-gld/gld mice developed proliferative synovitis. The arthritis was detectable by its histopathological features, which consist of proliferating synovial cells followed by pannus formation (16) (17) (18) (19) (20) . Synovial cell proliferation and pannus formation were prevented by RK-8 in stage I mice ( Fig. 2H and Table 1 ). RK-8 might directly kill the autoreactive T cells that are responsible for the arthritis. RK-8 completely ameliorated the arthritis in stage II and III MRL-gld/gld mice (Table 1) . Since synovial cells in rheumatoid arthritis are sensitive to apoptosis-inducing signals through Fas (29-31), RK-8 might directly kill these cells in vivo.
Effects of RK-8 on the serum level of autoantibodies
The gld gene induces abnormal activation of B cells, which causes a striking increase of serum Ig (particularly IgG) level and high titers of a variety of autoantibodies (16, 17, 20) . In MRL-gld/gld mice, the serum level of anti-DNA antibodies was elevated at 5 months of age. RK-8 decreased the levels of both anti-single stranded DNA and anti-double stranded DNA in stage II and III mice ( Table 1 ). The effect of RK-8 was optimum on stage III. Chronically activated peripheral B lymphocytes reportedly express Fas and are sensitive to apoptosis-inducing signals through Fas (12, 13) . RK-8 might directly kill the chronically activated B cells which produce autoantibodies. Alternatively it is likely that RK-8 has killed Fas-positive activated helper T cells, which are necessary for the activation of B cells and which is not inconsistent with the former notion.
In 5-week-old mice (stage I), RK-8 did not affect the subsequent production of autoantibodies, although it prevented young mice (stage I) from lymphoadenopathy, glomerulonephritis, arthritis, sialadenitis and vasculitis (Table 1) . These results suggest that autoreactive T cells and precursors of gld, but not B cells producing autoantibodies already exist in gld mice 5 weeks old (stage I), and that these T and precursor gld cells are directly eliminated by RK-8. The mechanism by which B cells producing autoantibodies are generated may be different from those of autoreactive T cells and gld cells (32) (33) (34) .
Discussion
Single administration of agonistic anti-mouse Fas mAb RK-8 was dramatically effective in FasL-deficient MRL-gld/gld mice with lymphoadenopathy and systemic autoimmune disease. Administrated RK-8 was shown to directly induce apoptosis on Fas-positive gld cells (Fig. 1B) and lymphoadenopathy was completely ameliorated. Single administration of anti-Fas mAb might similarly induce apoptosis on autoreactive T cells and autoantibody-producing B cells. The death of gld cells might not affect the effects of RK-8 on systemic autoimmune disease since the lymphoproliferative syndrome of lpr mice was reportedly separable from the systemic autoimmunity (35) (36) (37) .
The in vivo effects of RK-8 might be caused by neither the complement-mediated cell lysis nor the antibody-dependent cellular cytotoxicity, because administration of other six kinds of our prepared hamster and rat anti-mouse Fas mAb never showed significant cytocidal and therapeutic effects in vivo (data not shown). In addition, we observed many apoptotic bodies in the lymph nodes in RK-8-injected mice (Fig. 1) , indicating that in vivo therapeutic effects of RK-8 were not caused by complement-mediated cell lysis.
In the glomerular lesions of autoimmune mice (MRL-gld/ gld mice), inflammatory cells produce inflammatory cytokines such as TNF and IFN-γ, which may induce mesangial cell proliferation (38) . RK-8 might directly induce apoptosis in the infiltrating inflammatory peripheral T lymphocytes producing inflammatory cytokines in the kidney since the infiltrating cells were chronically activated peripheral T cells that are sensitive to Fas-mediated apoptosis (9) (10) (11) 23, 27, 28) . Then, RK-8 might indirectly reduce the number of mesangial cells. Another possibility, which does not conflict with the former possibility, is that RK-8 directly induces apoptosis in the proliferated mesangial cells, because the number of Fas-positive intraglomerular cells reportedly increases in lupus nephritis, focal glomerular sclerosis and IgA nephritis (39) .
The inflammation of MRL-gld/gld mice in salivary glands may be regarded as a model of Sjö gren's syndrome in humans as well as MRL-lpr/lpr mice (16, 17) . In Sjö gren's syndrome, the expression level of Fas reportedly increases on CD4 ϩ and CD8 ϩ peripheral T cells, and the abnormal balance between Fas and bcl-2 expressed in the lymphocytes is related to the lymphocytopenia associated with Sjö gren's syndrome (40) . The in vivo administration of agonistic antiFas mAb might eliminate abnormal Fas-positive lymphocytes in patients with Sjö gren's syndrome.
The Fas-FasL system plays important roles in both induction and prevention of autoimmune diseases. The Fas-FasL system was reported to be involved in the mechanisms responsible for thyrocyte disruption in Hashimoto's thyroiditis (41) and destruction of parietal cells in murine autoimmune gastritis (42) . By stimulation of the Fas-FasL system, any autoimmune disease would increase tissue disruption. On the other hand, peripheral autoreactive T and B cells have been suggested to be eliminated by the Fas-FasL system. Furthermore, abnormally increased synovial cells in rheumatoid arthritis are reportedly eliminated by the Fas-FasL system (30) . By stimulation of the Fas-FasL system, autoimmune disease would be recovered with elimination of autoreactive immunocytes and abnormally increased tissue cells. Here, we report the dramatic amelioration of autoimmune disease in MRL-gld/gld mice by a single administration of agonistic anti-Fas mAb RK-8. We never observed any damage in the kidney, salivary gland, lung, thyroid, stomach or other organs at 1 month after the administration of RK-8. If tissue damage had been induced by RK-8, it would be transient, as reported previously (24) . Finally, we suggest that stimulation of the Fas system by RK-8 recovers and/or prevents systemic autoimmune disease.
It should be determined whether or not anti-Fas mAb is effective in autoimmune mouse models other than the FasL mutant. We could not analyze the effect of RK-8 upon other autoimmune mice, at least not NZBϫNZW F 1 mice, because RK-8 is specific for an allotype of BALB/c and MRL. We could only analyze the effect of RK-8 on HTLV-1 p40 tax transgenic mice with a BALB/c background (43) . These mice developed severe arthritis, which local administration of RK-8 into the joints cured (31) . These results suggested that the systemic administration of an agonistic anti-Fas mAb into other autoimmune animals would be as effective as it was in MRL-gld/ gld mice.
We reported the therapeutic effects of intra-articular RK-8 on arthritis in HTLV-1 tax transgenic mice, and the finding that locally administered RK-8 directly induces apoptosis on synovial cells and infiltrating lymphocytes in autoimmune mice (31) . The therapeutic effects of local RK-8 remained for onlỹ 2 weeks. In contrast, the effects of systemic administration persisted for Ͼ6 months. Systemic administration may eliminate the autoreactive T cells not only in articulation but also in the whole body, which may account for the persisting effects.
Fas is expressed in various organs (44) . Administration of the anti-mouse Fas mAb Jo2 (1 mg/kg) was lethal in normal mice (25) . Our anti-Fas mAb RK-8 and RMF-2 (5 mg/kg) had no lethal effect on mice, and the results were essentially the same when a higher dose of RK-8 (50 mg/kg) was administrated (24) . The damage induced by RK-8 was transient and normal constitution was recovered within 1 month. Thus, side effects of RK-8 were less than those of anti-Fas mAb Jo2 (25) but also soluble FasL (45) . For the clinical application of anti-Fas mAb to systemic autoimmune disease, a new anti-human Fas mAb should be prepared with less side effects than soluble FasL (45) .
